Next-Generation Implantable Drug Delivery System with AI-Powered Real-Time Monitoring

Publication ID: 24-11857758_0005_PTD
Published: November 07, 2025
Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Next-Generation Implantable Drug Delivery System with AI-Powered Real-Time Monitoring,” Published Technical Disclosure No. 24-11857758_0005_PTD, Published November 07, 2025, available at https://archive.pr1or.art/24-11857758_0005_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,758.

Summary of the Inventive Concept

A revolutionary drug delivery system that integrates implantable devices with AI-driven decision-making, real-time monitoring, and personalized treatment to combat opioid overdoses and other medical emergencies.

Background and Problem Solved

The original patent disclosed a single-use drug delivery device for treating opioid overdoses. However, this invention has limitations, including the lack of real-time monitoring, limited adaptability to individual patients, and reliance on manual intervention. The next-generation system addresses these limitations by incorporating AI-powered decision-making, neural interfaces, and real-time monitoring to provide more effective and personalized treatment.

Detailed Description of the Inventive Concept

The inventive concept comprises an implantable drug delivery device with a neural interface for real-time monitoring of the recipient's physiological parameters, an AI-powered decision-making module for automatically detecting overdose events and triggering drug release, and a wearable device for detecting opioid overdose events. The system can deliver personalized cocktails of drugs tailored to the recipient's genetic profile and medical history. The biohybrid implantable device features a living cell-based sensor for detecting overdose events and a microfluidic drug delivery system for releasing therapeutic agents. The decentralized drug delivery network enables real-time monitoring and coordinated response to overdose events across a plurality of implantable devices.

Novelty and Inventive Step

The new claims introduce significant advancements over the original patent, including the integration of AI-powered decision-making, real-time monitoring, and personalized treatment. The use of neural interfaces, biohybrid sensors, and decentralized networks represents a paradigm shift in drug delivery technology, providing a more effective and adaptable solution for combating opioid overdoses and other medical emergencies.

Alternative Embodiments and Variations

Alternative embodiments may include variations in the neural interface design, AI algorithms, and sensor arrays. Additionally, the system could be adapted for use in different medical applications, such as diabetes management or cardiovascular disease treatment. The decentralized network could be expanded to include other devices, such as wearable fitness trackers or mobile health applications.

Potential Commercial Applications and Market

The next-generation drug delivery system has significant commercial potential in the medical device and pharmaceutical industries. The system's ability to provide personalized treatment and real-time monitoring addresses a critical need in the opioid epidemic, with potential applications in emergency response, hospital care, and outpatient treatment. The decentralized network and AI-powered decision-making capabilities also open up opportunities for remote patient monitoring and telemedicine.

CPC Classifications

SectionClassGroup
A A61 A61M5/14276
A A61 A61B5/4839
A A61 A61B5/4845
A A61 A61B5/4848
A A61 A61K9/0024
A A61 A61K9/0097
A A61 A61M5/44
A A61 A61M31/002
A A61 A61M37/0069
A A61 A61B5/01
A A61 A61F2250/0068
A A61 A61K31/485

Field of Art

Medical device technology, specifically implantable drug delivery systems with a focus on emergency medical interventions, particularly for opioid overdose treatment. Requires expertise in biomedical engineering, microfluidics, sensor design, and AI-driven medical technologies

Person of Ordinary Skill (PHOSITA) Profile

A biomedical engineer with advanced degrees, experienced in medical device design, familiar with neural interfaces, microfluidic systems, AI-powered medical technologies, and emergency drug delivery mechanisms. Possesses knowledge of biotechnology, sensor design, and adaptive medical systems

Obviousness Rationale

A PHOSITA would recognize that integrating AI-driven monitoring and personalized drug delivery into an existing implantable drug delivery device represents a predictable technological evolution. The source patent's foundational design for an implantable drug delivery system provides a clear technical framework that naturally suggests enhancement through real-time monitoring and intelligent decision-making technologies. The proposed variations represent logical extensions of existing medical device capabilities using well-established technological approaches.

Obvious Combinations & Variations

Source Patent Element
Implantable drug delivery device with a reservoir for containing drugs like naloxone
PTD Variation
Adding a neural interface and AI-powered decision-making module for automated drug release
Obviousness Reasoning
Integrating intelligent monitoring into drug delivery is a known technique in medical device design, representing a predictable improvement to existing implantable systems
Source Patent Element
Method of delivering drugs in response to physiological reactions
PTD Variation
Implementing personalized drug cocktails based on genetic profile and medical history
Obviousness Reasoning
Tailoring medical interventions to individual patient characteristics is a standard practice in precision medicine, representing an obvious design optimization
Source Patent Element
Device with temporary seal and drug reservoir for emergency intervention
PTD Variation
Incorporating living cell-based sensors and microfluidic delivery systems
Obviousness Reasoning
Advanced sensor technologies and microfluidic approaches are well-known in biomedical engineering, representing a finite set of predictable technological solutions
Source Patent Element
Single-use drug delivery device for treating opioid overdoses
PTD Variation
Creating a decentralized network of communicating implantable devices
Obviousness Reasoning
Networked medical devices are a standard technological approach for improving monitoring and intervention capabilities
Source Patent Element
Method of detecting physiological reactions to trigger drug delivery
PTD Variation
Implementing wearable devices with sensor arrays for overdose detection
Obviousness Reasoning
Extending drug delivery monitoring to wearable technologies represents a logical and predictable technological progression
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857758 and the comprehensive technological disclosures herein, a person of ordinary skill in the art would find the claimed innovations obvious and lacking in non-obvious inventive characteristics. The proposed variations represent straightforward technological extensions utilizing known techniques in medical device design, sensor technologies, and AI-driven medical interventions, thereby rendering potential patent claims obvious and non-patentable under 35 U.S.C. Section 103.

Original Patent Information

Patent NumberUS 11,857,758
TitleDrug delivery device and method
Assignee(s)Purdue Research Foundation